Suchergebnisse - "KE CHANGWEN"

PubPharm (19)

1

The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis

enthalten in: Nature immunology | 2024

von He, X. | Zhang, X. | Wu, B. | +35

2

Polymorphisms of IFN signaling genes and FOXP4 influence the severity of COVID-19

enthalten in: BMC infectious diseases | 2024

von Zhang, F. | Zhou, P. | Wang, L. | +5

3

Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects

enthalten in: Viral immunology | 2023

von Ji, R. | Zhang, J. | Liang, D. | +9

4

Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants

enthalten in: Nature communications | 2023

von Yu, H. | Liu, B. | Zhang, Y. | +36

5

The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody

enthalten in: Frontiers in cellular and infection microbiology | 2023

von Li, Y. | He, J. | Zhang, Y. | +9

6

Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants

enthalten in: Virology journal | 2022

von Liao, G. | Lau, H. | Liu, Z. | +32

7

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

enthalten in: Emerging microbes & infections | 2022

von Liang, H. | Zheng, P. | Wang, Q. | +16

8

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates

enthalten in: Emerging microbes & infections | 2022

von An, Y. | Li, S. | Jin, X. | +25

9

Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains

enthalten in: Cellular & molecular immunology | 2021

von Pan, T. | Hu, Z. | Hu, F. | +7

CommentIn: Signal Transduct Target Ther. 2021 Dec 17;6(1):430. - PMID 34921135

10

Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery

enthalten in: Nature communications | 2021

von Feng, C. | Shi, J. | Fan, Q. | +19